Modern aspects of application of palonosetron during chemotherapy


如何引用文章

全文:

开放存取 开放存取
受限制的访问 ##reader.subscriptionAccessGranted##
受限制的访问 订阅或者付费存取

详细

5НТз receptor antagonists are an integral part of complex antiemetic therapy. Palonosetron as a representative of latest generation 5НТз antagonists has new pharmacological characteristics: the longest half-life and the highest affinity for 5НТз receptors. The properties of palonosetron are the basis of its high efficiency, especially in the long-term period (cross-talk effect). According to published studies, palonosetron is the drug of choice among 5НТз receptor antagonists in one-day chemotherapy, and it has high efficacy in multi-day chemotherapy. Numerous studies have shown the efficacy and safety of palonosetron during chemotherapy in children.

全文:

受限制的访问

作者简介

O. Kondratieva

FSBI “RORC n.a. N.N. Blokhin" of RMH

M. Abramov

FSBI “RORC n.a. N.N. Blokhin" of RMH

PhD, Senior Researcher at the Department of Chemotherapy and Combined Treatment of Malignant Tumors

G. Vyshinskaya

FSBI “RORC n.a. N.N. Blokhin" of RMH

参考

  1. Antiemetic guidelines: MASCC/ESMO 2016;1. 2.
  2. Grunberg S.M., Koeller J.M. Palonosetron: a unique 5-MT3-receptor antagonist for the prevention of chemotherapy-induced emesis. Exp. Opin. Pharmacother. 2003;4(12):2297-2303.
  3. Rojas C., Thomas A.G., Alt J., Stathis М., Zhang J., Rubenstein Е.В., Sebastiani S., Cantoreggi S., Slusher B.S. Palonosetron triggers 5-HT3 receptor internalization and causes prolonged inhibition of receptor function. Eur. J. Pharmacol. 2010;626:193-99.
  4. Rojas C., Li Y., Zhang J., Stathis М., Alt J., Thomas A.G., Cantoreggi S., Sebastiani S., Pietra C., Slusher B.S. The Antiemetic 5-HT3 Receptor Antagonist Palonosetron Inhibits Substance Р-Mediated Responses In Vitro and In Vivo. J. Pharmacol. Exp. Ther. 2010;335(2):362-68.
  5. Gralla R., Lichinitser М., Van Der Vegt S., Sleeboom H., Mezger J., Peschel C., Tonini G., Labianca R., Macciocchi A., Aapro М. Palonosetron improves prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: results of a double-blind randomized phase III trial comparing single doses of palonosetron with ondansetron. Ann. Oncol. 2003;14:1570-77.
  6. Eisenberg Р., Figueroa-Vadillo J., Zamora R., Charu V., Hajdenberg J., Cartmell A., Macciocchi A., Grunberg S.; 99-04 Palonosetron Study Group. Improved Prevention of Moderately Emetogenic Chemotherapy-Induced Nausea and Vomiting with Palonosetron, a Pharmacologically Novel 5-HT3 Receptor Antagonist. Cancer. 2003;98(11): 2473-582.
  7. Aapro M.S., Grunberg S.M., Manikhas G.M., Olivares G., Suarez T., Tjulandin S.A., Bertoli L.F., Yunus F., Morrica B., Lordick F., Macciocchi A. A phase III, double-blind, randomized trial of palonosetron compared with ondansetron in preventing chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy. Ann. Oncol. 2006;17:1441-49.
  8. Kubota K., Saito M., Aogi K., Sekine I., Yoshizawa H., Yanagita Y., Sakai H., Inoue K., Kitagawa C., Ogura T. Control of nausea with palonosetron versus granisetron, both combined with dexamethasone, in patients receiving cisplatin- or anthracycline plus cyclophosphamide-based regimens. Support Care Cancer. 2016;24(9):4025-33.
  9. Musso M., Scalone R., Bonanno V., Crescimanno Л., Polizzi V., Porretto F., Bianchini C., Perrone T. Palonosetron (Aloxi) and dexamethasone for the prevention of acute and delayed nausea and vomiting in patients receiving multiple-day chemotherapy. Support Care Cancer. 2009;17:205-9.
  10. Tricco A.C., Blondal E., Veroniki A.A., Soobiah C., Vafaei A., Ivory J., Strifler L., Cardoso R., Reynen E., Nincic V., Ashoor H., Ho J., Ng C., Johnson C., Lillie E., Antony J., Roberts D.J., Hemmelgarn B.R., Straus S.E. Comparative safety and effectiveness of serotonin receptor antagonists in patients undergoing chemotherapy: a systematic review and network meta-analysis. BMC Medicine. 2016;14:216.
  11. Aapro M.S., Macciocchi A., Gridelli C. Palonosetron improves prevention of chemotherapy induced nausea and vomiting in elderly patients. J. Support. Oncol. 2005;3(5):369-74.
  12. Aapro M.S. Palonosetron as an anti-emetic and antinausea agent in oncology. Ther. Clin. Risk Manag. 2007:3(6) 1-12.
  13. Sepúlveda-Vildósola A.C., Betanzos-Cabrera Y., Lastiri G.G., Rivera-Marquez H., Villasis-Keever M.A., Del Angel V.W., Diaz F.C., López-Aguilar Е. Palonosetron Hydrochloride Is an Effective and Safe Option to Prevent Chemotherapy-induced Nausea and Vomiting in Children. Arch. Med. Res. 2008;39:601-6.
  14. Kovacs G., Wachtel A.E., Basharova E.V., Spinelli T., Nicolas Р., Kabickova Е. Palonosetron versus ondansetron for prevention of chemotherapy-induced nausea and vomiting in paediatric patients with cancer receiving moderately or highly emetogenic chemotherapy: a randomised, phase 3, double-blind, double-dummy, non-inferiority study. Lancet Oncol. 2016;17(3):332-44.
  15. Boccia R., Grunberg S., Franco-Gonzales Е., Rubenstein Е., Voisin D. Efficacy of oral palonosetron compared to intravenous palonosetron for the prevention of chemotherapy-induced nausea and vomiting associated with moderately emetogenic chemotherapy: a phase 3 trial. Support Care Cancer. 2013;21:1453-60.
  16. Coyne J.W. The first oral fixed-dose combination of Netupitant and Palonosetron for the treatment of Chemotherapy-induced nausea and vomiting. J. Adv. Pract. Oncol. 2016;7(1):66-70.
  17. National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology -Antiemesis. 2017;1.
  18. Siddiqui M.A., Scott L.J. Palonosetron. Drugs. 2004;64 (10):1125-32.

补充文件

附件文件
动作
1. JATS XML
下载

版权所有 © Bionika Media, 2017
##common.cookie##